This study focusses on patients with coronary artery disease (CAD), chronic heart failure (CHF), and both CAD and CHF. CAD is known to be the leading cause of death in people globally, and is responsible for 30% of all deaths in persons aged 35 and above. In addition, CHF is also known to be responsible for a large number of deaths and hospitalisations, with over 150,000 hospitalisations due to CHF occurring in the UK each year. Given this, it would be of great value to understand how many people in the UK are living with CAD, CHF, and CAD and CHF. The aim of the study is to estimate how frequent each of these conditions are in England, what issues and challenges patients with these conditions frequently face, and how much it costs the National health Service to treat patients with these conditions. We will also look at the implications on patients of these three disorders who also suffer from other diseases such as diabetes or who have had a heart attack in the past.
This is a cohort study with the overall objective of gaining a better understanding of the epidemiology, disease course, health resource utilisation (HRU), and treatment patterns of real-world patients with coronary artery disease (CAD), chronic heart failure (CHF), and CAD/CHF. The specific aims of the study are:
• To estimate the incidence and prevalence of CAD, CHF, and CAD/CHF
• To describe demographic and clinical characteristics of patients with CAD, CHF, and CAD/CHF
• To estimate the risk/incidence of complications (e.g. major cardiovascular events, bleeding) among patients with CAD, CHF, and CAD/CHF
• To describe HRU related to CAD and CHF complications among patients with CAD, CHF and CAD/CHF
• To describe treatment patterns, with a focus on standard of care, among patients with CAD, CHF, and CAD/CHF
• To estimate the risk/incidence of complications, compare the risk of complications, describe HRU related to CAD and CHF complications, and describe treatment patterns among subgroups of patients with CAD, CHF, and CAD/CHF defined by demographics, medical history, prior procedures, medication use, and risk scores
Jessica Jalbert - Chief Investigator - Regeneron Pharmaceuticals, Inc.
Jessica Jalbert - Corresponding Applicant - Regeneron Pharmaceuticals, Inc.
Alexander Cohen - Collaborator - King's College London (KCL)
Jean Baptiste Briere - Collaborator - Bayer AG
Jennifer Quint - Collaborator - Imperial College London
Julian Halcox - Collaborator - Swansea University
HES Accident and Emergency;HES Admitted Patient Care;HES Outpatient